MGX
Metagenomi, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.17
+0.86%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- -$0.64
- Revenue estimate
- $2.6M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.73
- EPS estimate
- -$0.55
- Revenue actual
- -$257.0K
- Revenue estimate
- $3.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -6.1%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.00
- PT range
- $5.00 – $7.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026